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Patched 1 regulates Smoothened by controlling sterol
binding to its extracellular cysteine-rich domain
Maia Kinnebrew1, Rachel E. Woolley2, T. Bertie Ansell3, Eamon F. X. Byrne2, Sara Frigui1,
Giovanni Luchetti1, Ria Sircar1, Sigrid Nachtergaele1, Laurel Mydock-McGrane4,
Kathiresan Krishnan4, Simon Newstead3,5, Mark S. P. Sansom3, Douglas F. Covey4,6,
Christian Siebold2*, Rajat Rohatgi1*
Smoothened (SMO) transduces the Hedgehog (Hh) signal across the plasma membrane in response to accessible
cholesterol. Cholesterol binds SMO at two sites: one in the extracellular cysteine-rich domain (CRD) and a second
in the transmembrane domain (TMD). How these two sterol-binding sites mediate SMO activation in response to
the ligand Sonic Hedgehog (SHH) remains unknown. We find that mutations in the CRD (but not the TMD) reduce
the fold increase in SMO activity triggered by SHH. SHH also promotes the photocrosslinking of a sterol analog
to the CRD in intact cells. In contrast, sterol binding to the TMD site boosts SMO activity regardless of SHH exposure.
Mutational and computational analyses show that these sites are in allosteric communication despite being
45 angstroms apart. Hence, sterols function as both SHH-regulated orthosteric ligands at the CRD and allosteric
ligands at the TMD to regulate SMO activity and Hh signaling.

Signals from the Hedgehog (Hh) pathway are transmitted across
the plasma membrane by Smoothened (SMO), a seven-helix transmembrane protein belonging to the G protein–coupled receptor
(GPCR) superfamily (1). SMO, however, does not directly bind
to extracellular ligands of the Hh pathway such as Sonic Hedgehog
(SHH). Instead, SHH is received at the cell surface by Patched 1
(PTCH1), a putative cholesterol transporter. In the absence of SHH,
PTCH1 inhibits SMO by restricting its access to cholesterol in the
membrane of the primary cilium, an antenna-like organelle that
projects from the cell surface and functions as a compartment for
Hh signaling (2, 3). SHH binds and inhibits PTCH1, thereby raising
cholesterol accessibility in the extracellular leaflet of the ciliary
membrane (2, 4). Cholesterol can then bind and activate SMO, which
transmits the signal to cytoplasmic effectors such as protein kinase
A (5–7). While membrane cholesterol can modulate the activity of
many GPCRs (8), cholesterol plays a unique role in Hh signaling
because it is both necessary and sufficient to activate SMO (5).
Elucidating the mechanism by which cholesterol activates SMO
promises to provide a paradigm for how receptor activity can be
controlled by cholesterol.
While SMO is clearly a sterol-responsive protein (9), its mechanism of activation is a topic of debate. In solving a crystal structure
of SMO that included both its transmembrane domain (TMD) and
extracellular cysteine-rich domain (CRD), we unexpectedly found a
cholesterol molecule bound in a shallow hydrophobic groove in the
CRD, positioned >10 Å above the extracellular leaflet of the plasma
membrane (Fig. 1A) (7, 10). This same groove is used by Frizzleds,
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the closest relatives to SMO in the class F GPCRs, to bind to the
fatty acid attached to WNT ligands (11). Ligand affinity assays confirmed that cholesterol can bind to the SMO CRD in solution and
structure-guided mutations that abrogated binding impaired signaling by SHH in both cultured cells and mouse embryos (5, 6, 12).
Together, these results led us to suggest that SHH, by inactivating
PTCH1, promotes cholesterol binding to the SMO CRD.
To stabilize SMO for structural studies, we included an inactivating mutation in the TMD (7). This mutation changed valine 329
(V3.40 in the class F Ballesteros-Weinstein nomenclature) in human
SMO (hSMO) to phenylalanine (V329F), which corresponds to
the V333F mutation in mouse SMO (mSMO). A subsequent crystal
structure of mSMO lacking this mutation in complex with the
synthetic agonist SAG bound at the extracellular end of the TMD
and the Nb8 nanobody (that recognizes the active conformation of
SMO) bound to the intracellular surface confirmed the presence of
the CRD-bound cholesterol (13). This structure also revealed a second
cholesterol molecule bound in the TMD positioned just below SAG
(Fig. 1A). While sterol binding to the TMD has not been demonstrated in solution, mutations (such as V333F) predicted to prevent
sterol binding to the TMD abolish SMO activity in cultured cells
(7, 13, 14). On the basis of cryo–electron microscopy structures,
a related model suggested that cholesterol molecules occupy various
positions in a putative tunnel that extends from the TMD site to the
CRD site (15). Simulation studies suggest that cholesterol molecules
may also bind to the lipid-facing surface of the TMD, in a crevice
between helices 2 and 3 adjacent to the TMD site (16).
The structural and mutational data summarized above raise the
following questions: Why does SMO have two (or more) cholesterol-
binding sites? While cholesterol is likely to be the physiological ligand at both sites, which of these sites is the orthosteric site (defined
as the signal-controlled site in SMO that is regulated by PTCH1)?
Comparisons between prior studies arguing for the importance of
one site over the other are hampered by differences in the mutations
introduced at the two sites, differences in the expression systems
used for SMO mutants, and differences in the assays used to measure
signaling strength (5–7, 13, 17). For example, studies of the CRD
1 of 17
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Fig. 1. Multiple ligand-binding sites control SMO activation. (A) SMO is composed of a CRD, TMD, and intracellular domain (ICD). Schematic of mSMO highlighting
three ligand-binding sites (the CRD, SAG, and TMD sites) along with interacting ligands. (B) Structure of hSMOC-BRIL-V329F in complex with cholesterol and SAG, with
close-ups shown in (C) and (D). (E to G) Superposition (G) of the hSMOC-BRIL-V329F:cholesterol:SAG complex (E) with the complex of mSMO with SAG, cholesterol, and
a nanobody (Nb8) (PDB 6O3C, 13) (F). (F) is considered an active-state SMO structure. (H) Histogram of the distances between the C atoms of hSMO V270 (V2.34) on helix
2 and hSMO F455 (F6.36) on helix 6 in atomistic simulations of mSMO (blue) and hSMOC (green), each bound to SAG and CRD cholesterol. Dashed lines indicate the
starting 2 to 6 distances, and the arrow indicates the increased distance between 2 and 6 caused by outward movement of 6 (fig. S1). (I) Snapshots showing the
outward movement of 6 in hSMOC (yellow, fig. S1D). The structure in green shows the distance between 2 and 6 at the start of the hSMOC simulation, and
the structure in blue shows active-state mSMO [Protein Data Bank (PDB) 6O3C] (fig. S1).

site used stable expression of mSMO mutants and measured the
transcription of the endogenous Hh target gene Gli1. In comparison,
analysis of the TMD site used transient overexpression of mSMO
mutants in conjunction with a synthetic luciferase-based reporter
system. To understand the roles of the CRD and TMD sites in SMO
activation and its regulation by PTCH1, we took three different approaches that rely on structure-guided mutagenesis and new sterol
analogs that selectively engage the TMD and CRD sites. Our results
support the model that sterol occupancy of both sites is required for
maximum SMO activity. The TMD site functions as an allosteric
site that influences the magnitude of both basal and SHH-induced
SMO activity, while the CRD site is the primary orthosteric site
that controls the SHH-driven increase in SMO activity. Thus,
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)
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cholesterol activates SMO by binding to two physically distant sites
on a GPCR family protein that communicate with each other
through an allosteric linkage.
RESULTS

Multiple ligand-binding sites can regulate SMO activity
Our experiments focused on the SMO ligand–binding sites depicted
in Fig. 1A: the two sterol-binding sites, referred to as the CRD and
the TMD sites, and the SAG-binding site that sits just above the TMD
site closer to the extracellular side of the membrane (10, 18, 19). The
V333F mutation (V329F in human numbering or V3.40F) in the
TMD site abolishes mSMO activation by the native ligand SHH, an
2 of 17
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cholesterol–binding sites in SMO activation in response to SHH
using diverse approaches.
The CRD site mediates SHH-induced increases in
SMO activity
Which of the cholesterol-binding sites are regulated by PTCH1? In
other words, which site becomes occupied by cholesterol when SHH
binds and inactivates PTCH1? To address this question, we generated
structure-guided mutations in the CRD and TMD sites of mSMO
designed to disrupt hydrogen-bonding interactions with the 3-
hydroxyl of cholesterol: D99A in the CRD site and Y398F in the
TMD site (Fig. 2A). The D99A mutation in the mSMO CRD (D95A
in hSMO) abrogated binding of purified hSMOC-BRIL-V329F to
cholesterol in a previously validated ligand affinity assay (fig. S2B)
(7). While the field lacks an analogous solution–based assay to
measure the interaction between cholesterol and the TMD site in
SMO, atomistic simulations confirmed that Y398 in mSMO engages
in a hydrogen-bonding interaction with the 3-hydroxyl of cholesterol (Fig. 2A and fig. S2C).
These mutants were stably expressed in Smo−/− cells to exclude
signaling from endogenous WT mSMO. The abundances of these
mutant proteins in the whole cell and the primary cilium were comparable (fig. S2, D to F). To evaluate the change in the signaling
activity of mSMO variants in response to SHH, we measured the
fold increase in the abundance of endogenous Gli1 mRNA, a direct
transcriptional target of Hh signaling. The fold change in Gli1 mRNA
abundance (rather than the absolute magnitude of Gli1 mRNA
abundance) is the best metric for SHH-induced changes in SMO
activity since it will be less sensitive to changes in SMO protein
abundance, the SMO conformational ensemble, or SMO subcellular
localization (all of which can be altered as unintended consequences
of mutations). For example, if a mutation reduces both basal and
SHH-stimulated SMO signaling by the same magnitude, then the
fold increase in SMO signaling (the ratio of SHH-stimulated to basal
activity) will remain unchanged. Such a mutation may affect SMO
abundance and SMO subcellular localization or bias the SMO conformational ensemble toward inactive states but probably does
not affect the SHH-driven change in SMO activity.
The D99A mutation in the CRD site impaired SHH-induced
mSMO activation, reducing Gli1 induction from 64- to 13-fold
(Fig. 2B). In contrast, mSMO-Y398F, which carries a corresponding
mutation in the TMD site, remained fully responsive to SHH,
suggesting that this site is less important for the fold increase in
mSMO activity seen when PTCH1 is inactivated by SHH (Fig. 2B).
mSMO-WT and mSMO-Y398F were also equally responsive to
20(S)-hydroxycholesterol [20(S)-OHC], a CRD ligand whose activity
is reduced by the D99A mutation (Fig. 2C) (5, 7). In summary, the
Y398F mutation in the TMD site did not change the fold increase in
Gli1 abundance triggered by either CRD ligands or inactivation of
PTCH1 by SHH.
To further understand the relationship between the CRD and
TMD cholesterol–binding sites, we measured the response of
mSMO-D99A and mSMO-Y398F to increasing concentrations of
SHH and SAG (Fig. 2, D and E). The Y398F TMD mutation reduced
the potency of SHH, measured by the concentration of SHH required
to half-maximally increase Gli1 mRNA [also called the median
effective concentration (EC50)], but did not change the maximum
fold increase in Gli1 abundance (known as the efficacy) (Fig. 2D). In
contrast, both the potency and the efficacy of SHH were reduced by
3 of 17
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observation used to argue that the TMD site is more important for
SMO regulation by PTCH1 (13). However, V333F may simply
stabilize mSMO in an inactive state. Consistent with this possibility,
mSMO-V333F cannot be activated by any SMO agonists, including
those that directly bind to the SAG or the CRD sites (7). mSMO-
V333F fails to localize in primary cilia in response to SHH, a compartment where SMO must accumulate to activate downstream Hh
signaling (fig. S1, A and B).
To understand the relationship between ligand binding and
activation, we determined the crystal structure of hSMOC-BRILV329F in a complex with cholesterol (bound to the CRD site) and
SAG at 3.0-Å resolution (Fig. 1B, table S1). This hSMO protein
[identical to the one used in our prior structural work (7)] lacks
the disordered C-terminal intracellular domain (Fig. 1A) and
carries both the inactivating V329F mutation and a BRIL domain
inserted in the third intracellular loop to facilitate crystallization.
Cholesterol and SAG occupy positions in our structure similar to
those reported for complexes of SMO with SAG alone or cholesterol
alone (7, 19), showing that these two agonists can bind even when
SMO is mutationally stabilized in an inactive state (Fig. 1, C and D).
We compared our inactive-state structure to the structure of mSMO
bound to SAG, cholesterol, and a nanobody (Nb8) raised against
activated (SAG-bound) SMO (Fig. 1, E to G) (13). The latter structure was proposed to represent an active-state structure because it
revealed an outward movement of the intracellular ends of the
helices 5 and 6, considered to be a hallmark of GPCR activation
that allows coupling to downstream signaling components in the
cytoplasm. Opening of the cytoplasmic face of the TMD, stabilized
by Nb8 binding, was associated with binding of a second cholesterol
molecule to the TMD site (Fig. 1F). Consistent with functional data
showing that the V333F mutation locks mSMO in an inactive state
regardless of ligand binding (fig. S1, A and B), the 5 and 6 helices
in our structure were positioned in a more inward orientation closer
to the central axis of the TMD (Fig. 1G).
With these high-resolution structures as starting points, we performed atomistic simulations of the hSMO and mSMO structures.
We reverted the phenylalanine mutation at residue 329 in hSMO to
the wild-type (WT) valine and removed Nb8 from mSMO during
these simulations to probe the effects of ligand binding on the
5- and 6-helical movements associated with GPCR activation.
The outward movement of 5/6 in the mSMO:SAG:cholesterol:Nb8
structure causes an increased distance between helices 2 and 5/6,
hereafter referred to as the “open” active conformation (Fig. 1H).
mSMO remained in the open conformation, regardless of whether
it was bound to SAG and CRD-cholesterol, CRD-cholesterol only,
or present in the ligand-free apo state (Fig. 1H and fig. S1, E and F).
In contrast, one replicate simulation of hSMO bound to SAG and
CRD-cholesterol (that started with SMO in a closed conformation)
showed partial activation as measured by outward movement of the
5 and 6 helices (Fig. 1, H and I, and fig. S1, C and D). While it
is rare to observe substantial conformational changes at atomistic
simulation time scales (in the absence of enhanced sampling),
these intermediary conformations have been previously observed
in equilibrium simulations of other GPCR systems (20, 21). Together, these structural and computational analyses suggested
that SMO can adopt an active-state conformation even without
cholesterol bound to the TMD site, which has been presented as
an obligate driver of SMO activation (13, 15). Thus, we decided
to experimentally test the requirement of the CRD and TMD
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D99 in the CRD and Y398 in the TMD make hydrogen bonds with the 3-hydroxyl of cholesterol. (B and C) Fold change in endogenous Gli1 mRNA abundance in response
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cholesterol in modulating signaling activity that propagates from
the CRD cholesterol (Fig. 2H). Cholesterol binding to the CRD
reduces information flow through residues in the CRD face/linker
region (fig. S3, A and B). In contrast, information flow through a
subset of residues on the 6 extension or lining the helical bundle
(including Y398) is enhanced upon CRD cholesterol binding (fig. S3,
A and B). This suggests that cholesterol binding to SMO favors information flow through the 6/TMD pathway, while the CRD face/
linker pathway is more important in the apo state. An additional
intermediate sterol-binding site has been proposed in proximity to
the linker region of SMO (15). However, we did not find cholesterol
binding to this site to be stable in simulations. The presence of this
third cholesterol destabilized both the CRD and the TMD-bound
cholesterol molecules in SMO (fig. S3, C to H).
Together, this analysis suggests that the CRD cholesterol–binding
site is primarily responsible for the increase in SMO activity when
PTCH1 is inactivated by SHH. The TMD functions as a long-range
allosteric site to tune SMO activity.
The TMD site regulates basal SMO signaling in the
absence of SHH
SMO, similar to many GPCRs, demonstrates basal signaling activity
even in the absence of activating ligands. Ligand-independent signaling activity is explained by the fact that GPCRs are not on-off
switches but rather populate an ensemble of conformations determined by a free energy landscape (23). Receptor conformations of
lower energy are more populated; ligands (including lipids) can alter
this free energy landscape to favor a population of conformations
with specific signaling activities (24, 25). Basal receptor activity is
proposed to be a consequence of the fact that even in the absence of
agonists, a small number of receptors at any given snapshot in time
are in an active conformation.
The absolute abundance of Gli1 in the absence of SHH can be
used as a measure of basal SMO activity. While the basal signaling
activities of mSMO-WT and mSMO-D99A were comparable,
mSMO-Y398F and mSMO-D99A/Y398F were both five times less
active in the absence of SHH (Fig. 3A). Since the maximum SHH-
stimulated Gli1 abundance was also reduced by a similar magnitude,
the fold increase in mSMO-Y398F activity remained unchanged.
This analysis shows that only measuring the absolute level of a transcriptional reporter such as Gli1, without accounting for differences
in basal reporter activity, will lead to the erroneous conclusion that
the Y398F mutation in mSMO compromises SHH responsiveness.
The Y398F mutation likely alters the energy landscape of mSMO
such that both basal and stimulated signaling activities are reduced,
but the change in signaling activity induced by SHH is unaltered.
Cyclopamine, a sterol-like inhibitor of mSMO, is an inverse
agonist that suppresses the basal activity of mSMO-WT and mSMO-
D99A (Fig. 3B) (26). However, cyclopamine had no effect on the
basal activity of mSMO-Y398F (Fig. 3B). In an important control,
cyclopamine could still inhibit mSMO-Y398F signaling in response
to SHH, showing that this mutation did not simply prevent the
interaction between SMO and cyclopamine (fig. S4A). These data
suggested that constitutive cholesterol occupancy of the TMD
site sets the basal level of SMO signaling. In support of this idea,
depletion of membrane cholesterol reduced the basal activities of
mSMO-WT and mSMO-D99A to the level seen in mSMO-Y398F
(Fig. 3C). Cholesterol depletion had no effect on the basal activity
of mSMO-Y398F.
5 of 17
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the D99A CRD mutation. The residual SHH responsiveness seen in
mSMO-D99A could be caused by two reasons: (i) This mutation
fails to completely eliminate cholesterol binding to the CRD in cells,
or (ii) SHH (acting indirectly through PTCH1) also regulates
cholesterol accessibility to the TMD site. Introduction of a second
mutation (Y134F) in the hydrogen-bonding network that positions
cholesterol in the CRD (fig. S2A) further reduced responsiveness to
both SHH and 20(S)-OHC, highlighting the central regulatory role
of the mSMO CRD in PTCH1 regulation (fig. S2, G and H).
To test potential long-range interactions between the CRD and
TMD sites, located 45 Å apart, we compared the signaling activity
of the D99A and Y398F single mutants to the mSMO-D99A/Y398F
double mutant (formally known as a double-mutant cycle analysis).
mSMO-D99A/Y398F was completely unresponsive to SHH (Fig. 2D).
In a key control that demonstrated protein integrity, all three mutant mSMO proteins supported the same maximum fold increase in
Gli1 mRNA in response to SAG (Fig. 2E). The reduced potency of
SAG in cells expressing mSMO-Y398F and mSMO-D99A/Y398F is
likely related to the proximity of the Y398 residue to the SAG-binding
site (Fig. 2A). Given that we lack an assay to measure binding of
cholesterol to the TMD, the marked lack of SHH-induced signaling
activity in mSMO-D99A/Y398F provides indirect (but important)
evidence that the Y398F mutation disrupts the TMD site.
If the CRD and TMD-binding sites were independent, then we
would predict an additive decrease in SHH responsiveness in the
mSMO-D99A/Y398F double mutant compared to the individual
single mutants. Purely additive effects of the D99A and Y398F mutations would predict an EC50 of ~24 nM and a maximum induction
of ~20-fold in the D99A/Y398F double mutant. However, the complete abrogation of activity in the double mutant represents a greater
than additive effect and provides evidence for long-range allosteric
communication between the CRD and TMD sites. This allosteric
interaction explains prior observations that mutations in the TMD
site can reduce the potency of SHH even if SHH regulates cholesterol
occupancy of the CRD (Fig. 2D) (13).
Last, we performed atomistic simulations of mSMO in the ligand-
free state or with cholesterol bound to the CRD site alone, the TMD
site alone or both sites simultaneously. To compare the dynamic
movements of mSMO domains in these four states, we calculated
the root mean square fluctuation (RMSF) of residues across the
simulations. RMSF values for the CRD were similar when a single
cholesterol was bound to either the CRD or TMD (Fig. 2F). In contrast,
when both sites were occupied, the CRD fluctuations were markedly
reduced, suggesting cooperative interactions between the CRD and
TMD sites. To further dissect this observation, we calculated the
flow of information (also known as current) through mSMO using
a recently developed method for calculation of allostery that can
include lipids in pathway calculations (22). Two main pathways of
information flow between the CRD pocket and 6/7 were revealed:
(i) the extracellular extension of 6 (Fig. 2G, solid arrow) and (ii) a
ladder of residues on the opposing CRD face and the mSMO linker
domain (Fig. 2G, dashed arrow). The CRD-bound cholesterol
is a major contributor to the information flow, with one of the
highest flow values compared to all other residue and lipid nodes
(Fig. 2, G and H). The contribution of the TMD cholesterol to the
information flow is lower than that of the CRD cholesterol. When
both the TMD and CRD cholesterol sites are occupied, information
flow through the CRD cholesterol is reduced, while the TMD
cholesterol is unaffected, consistent with the role of the TMD
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cyclopamine = 0.0009, D99A untreated versus cyclopamine = 0.0013, Y398F untreated versus cyclopamine = 0.2262, and D99A/Y398F untreated versus cyclopamine =
0.0622. (C) WT serum versus LDS < 0.0001, WT serum versus LDS + cholesterol = 0.0604, D99A serum versus LDS < 0.0001, D99A serum versus LDS + cholesterol = 0.4310,
Y398F serum versus LDS = 0.6333, and D99A/Y398F serum versus LDS = 0.7885. (G) WT versus mSMO-ΔCRD (untreated) < 0.0001, WT versus mSMO-ΔCRD-Y398F (untreated)
= 0.5700, and mSMO-ΔCRD versus mSMO-ΔCRD-Y398F (+SHH) = 0.0073.
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)

3 June 2022
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The CRD site is required for SHH-induced SMO activation
Our previous experiments showed that the increase in SMO activity
in response to SHH depends critically on the CRD cholesterol–
binding site. However, mSMO carrying mutations in the CRD site
retains some SHH responsiveness (Fig. 2D), as has been noted previously (17). Perhaps cholesterol occupancy of both the CRD and
TMD sites is regulated by PTCH1?
To disentangle the contributions of the CRD and TMD sites
using a different strategy, we identified a sterol analog capable of
binding and activating SMO selectively through its TMD site.
Oxysterols such as 20(S)-OHC are selective CRD agonists, so we
reasoned that other sterol analogs may show a preference for the
TMD site (27–29). We focused on KK174, which contains diazirine
and alkyne groups on the iso-octyl chain of cholesterol (Fig. 4A) (30).
To measure the direct effect of KK174 on SMO in a purified
system, we established a pull-down assay to measure the interaction
between purified hSMOC and the active-state selective Nb8 (Fig. 4B).
In the absence of any ligands, hSMOC was poorly captured by
Nb8-coupled beads. SAG or the CRD-selective agonist 20(S)-OHC
promoted the interaction between hSMOC and Nb8. Thus, a CRD
agonist in a purified system can activate SMO without the need to
supply an additional TMD agonist. KK174 also promoted the interaction between hSMOC and Nb8, showing that it can directly
activate SMO.
KK174 met several criteria for a TMD-selective agonist. Well-
established inactivating mutations in the CRD site (D99A) or the SAG
site (D477G) failed to impair responses to KK174 (Fig. 4, C and D),
showing that it does not activate SMO through the CRD or the SAG
sites. This conclusion is also supported by the observation that
KK174 does not compete for binding of SMO to 20(S)-yne–coupled
beads (Fig. 4E), showing that KK174 does not bind to the CRD (28).
In addition, the V333F mutation previously used to obstruct the
TMD site blocked the signaling response to KK174 (Fig. 4F), showing
that KK174 requires the integrity of the TMD site (13).
To probe the activity of KK174 on the isolated TMD, we
used mSMO-CRD. KK174 could activate mSMO-CRD but not
mSMO-CRD-Y398F, demonstrating that Y398 in the TMD is
required for KK174 activity (as it is for cholesterol activity) (fig.
S5B). KK174 could activate signaling in cholesterol-depleted cells
expressing mSMO-CRD, showing that it can mimic cholesterol
(fig. S5C).
Unlike cholesterol, which binds to both the CRD and TMD sites,
KK174 allowed us to selectively probe the TMD-binding site in SMO.
We took advantage of our previous observation that mSMO-CRD,
when fused to yellow fluorescent protein at its N terminus (YFPmSMO-CRD; Fig. 5A) and stably expressed in Smo−/− cells, shows
very low basal signaling activity (comparable to that of YFP-tagged
mSMO-WT) (28). The complete elimination of the CRD in YFPmSMO-CRD allows unequivocal evaluation of the role of the
TMD-site in SMO activation. Both YFP-mSMO and YFP-mSMOCRD (Fig. 5A) were equally responsive to SAG, demonstrating
equivalent signaling capacity (Fig. 5B). KK174 also activated both
proteins with similar EC50 values (Fig. 5C). These data establish the
integrity of the SAG and TMD sites in YFP-mSMO-CRD: Ligands
that engage each of these sites retain their agonist properties. By
extension, if the SMO TMD site is the primary focus of PTCH1
regulation, then YFP-mSMO-CRD should remain as responsive
to SHH as YFP-mSMO. Contrary to this prediction, however, YFPmSMO-CRD was markedly less responsive to SHH (Fig. 5D),
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A truncation mutant of mSMO lacking the entire CRD (mSMO-
CRD) displays much higher basal signaling compared to mSMO-WT
when expressed in cells (7). We previously proposed that CRD
interactions with the TMD and the linker domain stabilize the
inactive state of SMO (7). To directly test the role of the CRD in
controlling SMO activity, we fused the active-state selective Nb8 to
mVenus (Nb8-mVenus) (13) and probed its interactions with nonfluorescent variants of hSMOC using fluorescence-detection size
exclusion chromatography (FSEC). Nb8 was initially selected to
preferentially bind an activated conformation of mSMO, one in
which the 5/6 helices are displaced outward (Fig. 1F). The stable
interaction of Nb8-mVenus with hSMOC will induce a shift to
higher molecular weights (shorter retention times) on the FSEC trace.
In the absence of any added ligands, only a fraction of hSMOC
formed a complex with Nb8 after a 1-hour incubation, as shown by
a double peak in the FSEC trace (Fig. 3D). However, a longer incubation of 24 hours allowed the entire population of hSMOC to bind
Nb8-mVenus. The slow kinetics of binding likely reflect the slow
spontaneous conversion of hSMOC to an active conformation,
which is recognized and then stabilized by Nb8 binding. The fraction of hSMOC that is bound to Nb8 at 1 hour likely represents
molecules that adopted an activated conformation during purification. In contrast, the entire population of Nb8-mVenus shifted
to a higher molecular weight within 1 hour when incubated with
hSMOC lacking the CRD (hSMOC-CRD), demonstrating much
more rapid binding of hSMOC to the active-state Nb8 when the
CRD is removed (Fig. 3E). In a control experiment, we did not detect
an interaction between Nb8-mVenus and the inactive hSMOCBRIL-V329F (Fig. 3F) (7). Using a completely purified system, these
data show a direct role of the CRD in preventing the TMD from
adopting an active state (and consequently triggering downstream
cytoplasmic signal propagation).
Given this key role of the CRD in suppressing TMD activity,
mSMO-CRD provided an opportunity to study the TMD site in
isolation. Similar to its effect on mSMO-WT (Fig. 3A), the Y398F
mutation markedly reduced the basal activity of mSMO-CRD
(Fig. 3G). As reported previously, mSMO-CRD signaling is increased modestly by SHH (an observation that has been used to argue
that the TMD site is the major PTCH1-regulated site) (Fig. 3G)
(13, 27). The Y398F mutation also eliminated SHH responsiveness
of mSMO-CRD. Thus, the integrity of the TMD site is required
for both the high basal activity and the SHH responsiveness of
mSMO-CRD. These results also confirm that the Y398F mutation
(which has no effect on the SHH-induced fold increase in mSMO
activity; Fig. 2B) disrupts the sterol-binding site in the TMD. In important controls, the abundance of mSMO-CRD-Y398F was similar
to mSMO-CRD in our cell lines (fig. S4B), and mSMO-CRDY398F could be activated by SAG (showing protein integrity) but
not by cholesterol (fig. S4, C and D).
Our results suggest that constitutive cholesterol binding to the
TMD site in SMO changes the energy landscape of SMO such
that basal signaling activity is increased. The CRD provides a restraining influence, preventing full SMO activation, until SHH
(by inactivating PTCH1) increases outer leaflet cholesterol accessibility to the point that the CRD site is occupied (4). This model
explains the modest SHH responsiveness of mSMO-CRD: An
increase in cholesterol accessibility triggered by SHH will lead to
greater occupancy of the TMD site and hence an increase in signaling activity.
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highlighting the essential requirement of the CRD for SHH-triggered signaling. These results also show that KK174 does not act on
PTCH1 because in this scenario, the effect of KK174 and SHH on Gli1
mRNA induction should be similar.
If SHH and KK174 regulate different sites on SMO, then we
would predict an additive or synergistic effect on signaling if both
ligands are applied simultaneously. If SHH and KK174 both regulate
the TMD, then these molecules should show a competitive interaction.
Consistent with our previous discovery of an allosteric interaction
between the CRD and TMD sites (Fig. 2, D and F), SHH increased
the potency (or decreased the EC50) of KK174 in cells expressing
YFP-mSMO (Fig. 5E). Deletion of the CRD eliminated the potentiating effect of SHH on mSMO activation by KK174, consistent with
SHH (and PTCH1) regulating mSMO through the CRD (Fig. 5F).
Together, an orthogonal experimental strategy again supported the
conclusion that the primary binding site on SMO that is regulated
by PTCH1 is the CRD.
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)

3 June 2022

PTCH1 inhibits sterol binding to the SMO CRD
If PTCH1 inhibits SMO by preventing sterol access to the CRD, then
SHH-mediated inactivation of PTCH1 should lead to enhanced
binding of sterols to the CRD. To test this prediction, we developed
the oxysterol analog 6-azi-20(S)-yne (Fig. 6A) to measure sterol-CRD
interactions in the native membrane environment of intact cells
using photoaffinity labeling. This bifunctional analog is decorated
with a terminal alkyne compatible with click chemistry and a photocrosslinkable diazirine. 6-azi-20(S)-yne activated Hh signaling in a
manner similar to 20(S)-OHC (Fig. 6B) with an EC50 of ~0.5 M
(fig. S6A). 6-azi-20(S)-yne activates mSMO through its CRD because
a point mutation (Y134F; fig. S2A) in the CRD site abrogated 6-azi20(S)-yne–mediated signaling (Fig. 6B). To measure the interaction
of YFP-mSMO with 6-azi-20(S)-yne, live cells were irradiated with
365 nm light to activate the diazirine and initiate covalent labeling
of interacting proteins (31). YFP-mSMO was then immunopurified
from detergent extracts, and on-bead click chemistry was used to
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attach a biotin to the YFP-mSMO-sterol adduct (Fig. 6C). Western
blotting with streptavidin was used to measure the amount of
YFP-mSMO photo-labeled by 6-azi-20(S)-yne.
To test the specificity of CRD photolabeling by 6-azi-20(S)yne, we used YFP-mSMO-WT and YFP-mSMO variants carrying mutations in the CRD site (Y134F) or the TMD site (V333F).
When used at a concentration of 1 M, 6-azi-20(S)-yne demonstrated specific cross-linking to YFP-mSMO variants with an
intact CRD (Fig. 6D): YFP-mSMO-Y134F was not labeled, while
YFP-mSMO-V333F was labeled at a similar efficiency as YFPmSMO-WT. Photolabeling of YFP-mSMO-V333F was abolished
when the CRD was deleted (Fig. 6D). As expected, the photolabeling of YFP-mSMO was strictly dependent on ultraviolet (UV)
irradiation. All experiments used a concentration of 1 M 6-azi20(S)-yne, since nonspecific photolabeling was observed at 10 M
(Fig. 6D).
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)

3 June 2022

We measured YFP-mSMO-WT photolabeling by 6-azi-20(S)-yne
in the presence of PTCH1-WT or a widely used deletion mutant of
PTCH1 (PTCH1-L2). PTCH1-L2 can inhibit SMO activity but
cannot bind or be inactivated by SHH (32, 33). The addition of SHH
increased YFP-mSMO-WT photolabeling by 6-azi-20(S)-yne in
cells expressing PTCH1-WT but failed to change YFP-mSMOWT photolabeling in cells expressing the SHH-unresponsive
mutant PTCH1-L2 (Fig. 6E). These data suggest that PTCH1 can
reduce the access of the SMO CRD to 6-azi-20(S)-yne. PTCH1 itself
could be photolabeled by 6-azi-20(S)-yne. Labeling of PTCH1 by
6-azi-20(S)-yne was diminished by SHH, an inhibitor of PTCH1 transport activity (Fig. 6F). As predicted, photolabeling of PTCH1-L2
was not blocked by SHH.
In summary, our data provide direct support for the model that
PTCH1 uses its transport activity to regulate SMO by reducing the
binding of a sterol to its CRD. Our results are in agreement with
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untreated versus SHH = 0.0288 and PTCH1-DL2 untreated versus SHH = 0.6955. (F) PTCH1-WT untreated versus SHH = 0.0026 and PTCH1-L2 untreated versus SHH = 0.7730.

prior work showing that SHH and PTCH1 can regulate SMO labeling
by a cholesterol analog that undergoes spontaneous (not UV-catalyzed)
covalent attachment to the CRD (12).
DISCUSSION

Despite a bounty of structural studies, the mechanism by which
sterols activate SMO remains uncertain. The presence of multiple
ligand-binding sites in SMO raises the question of which site is the
orthosteric site (or the primary focus of regulation by PTCH1) and
which site functions as an allosteric site. While GPCRs can be regulated by multiple ligands at orthosteric and allosteric sites, SMO is
unusual in two ways. First, both the TMD and CRD sites of SMO
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)
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engage the same ligand, cholesterol. Second, the high abundance of
cholesterol in the plasma membrane of vertebrate cells means that
SMO likely never exists in a truly “ligand-free” state (34, 35). This is
particularly true of the TMD, positioned within the interior of the
membrane bilayer where cholesterol represents one of every three
lipid molecules. Approximately 20 molecules of cholesterol are predicted to be present in the lipid layer immediately surrounding the
TMD (3). For example, simulation studies provide support for
cholesterol molecules located between helices 2 and 3 (16). In
contrast, the CRD site is positioned >10 Å above the plane of the
plasma membrane (5, 7). Access to the CRD presents a substantial
energetic barrier because it requires a hydrophobic cholesterol
molecule to completely desorb from the membrane and traverse
10 of 17
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Fig. 7. A model for SMO activation by dual sterol binding to the TMD and CRD sites. (A) Linked equilibria showing four states of SMO defined by sterol occupancy of
the CRD and TMD sites. At physiological membrane cholesterol levels, SMO mostly exists in state II, with cholesterol bound to the TMD driving basal signaling activity.
PTCH1 inhibits the transition from state II to the fully active state IV by reducing accessible cholesterol in the outer leaflet of the membrane. (B) A cartoon depicting the
binding of cholesterol to the TMD site (cyan) or the CRD site (green) at increasing levels of accessible cholesterol in the membrane outer leaflet. Under basal (no SHH)
conditions, the TMD site is largely occupied, while the CRD site is largely empty. PTCH1 overexpression (especially above physiological levels) can reduce cholesterol
binding to both sites by depleting the membrane outer leaflet of accessible cholesterol. Conversely, SHH increases cholesterol binding to the CRD by inactivating PTCH1.
(C) Two models for the regulation of SMO signaling by PTCH1. In model 1, PTCH1 depletes the membrane of accessible cholesterol, indirectly inhibiting SMO, while in
model 2, PTCH1 directly removes cholesterol from the SMO CRD.

an aqueous environment (36). These considerations suggest that
the CRD site is better suited to be regulated by PTCH1 than the
cholesterol-immersed TMD site, at least in vertebrate plasma membranes that contain 30 to 50 mole percent (mol %) of cholesterol.
The TMD site may play a more central role in PTCH1 regulation in
insects, whose membranes have markedly lower amounts of sterols
(<5 mol %; most of which is ergosterol) (37, 38). The CRD from
Drosophila SMO does not bind oxysterols in vitro (28, 39).
On the basis of three different lines of investigation, we propose
a model for SMO activation (Fig. 7A) that considers four states
of SMO with varying signaling activities. When both the CRD and
TMD sites are unoccupied, SMO has minimal activity (as seen for
SMO-D99A/Y398F; Fig. 2D). When both the CRD and TMD sites
are occupied by cholesterol in response to SHH, SMO has maximal
signaling activity. Two additional states are defined by sterol binding to either the CRD or the TMD site, with the other remaining
empty. In the absence of SHH, the abundance of cholesterol in the
membrane leads to occupancy of the TMD site, driving basal signaling activity. However, PTCH1 uses its transporter activity to reduce
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)
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accessible cholesterol in the outer leaflet of the ciliary membrane (2, 4),
ensuring that the CRD site remains unoccupied and, consequently, the
CRD maintains its inhibitory restraint on the TMD. When PTCH1 is
inactivated by SHH, cholesterol binds to the CRD because the concentration of accessible cholesterol in the outer leaflet of the membrane
rises (4), driving full SMO activation. Both the CRD and TMD sites
do not have to be occupied for SMO activation: The SHH-induced fold
increase in SMO activity is maintained even when the TMD site is
mutated (e.g., in mSMO-Y398F). On the other hand, basal signaling
activity (in the absence of SHH) is driven largely by cholesterol binding to the TMD even in the presence of CRD mutations (Fig. 3).
A key observation that emerged from our experiments is that
mutation of the SMO TMD site reduces both the basal and SHH-
induced levels of SMO signaling but leaves the fold increase (the
ratio of SHH-induced to basal activity) intact. Our results are in
agreement with previous data showing that mutations in the TMD
site reduce absolute levels of SMO signaling, a result that was used
to argue that the TMD site is the PTCH1-regulated orthosteric site
in SMO (13). However, our observation that the SHH-induced fold
11 of 17
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MATERIALS AND METHODS

Constructs and plasmids
SMO constructs
Full-length untagged mSMO mutants (D99A, Y134F, D99A/Y134F,
Y398F, D99A/Y398F, V333F, and D477G) were generated using the
QuikChange method. Amino acid residues 67 to 184 were deleted
from mSMO to generate mSMO-CRD, and point mutants (CRDY398F, CRD-V333F) were introduced into the mSMO-CRD
backbone. YFP-tagged SMO constructs (YFP-mSMO and YFP-
mSMO-CRD) were generated by introducing the YFP tag downstream of the mSMO signal sequence, as described previously (45).
All constructs were cloned into the pMSCVpuro vector to enable
retrovirus generation for stable cell line construction.
For the Nb8 binding studies shown in Figs. 3 and 4, variants of
the hSMO protein lacking its disordered C-terminal cytoplasmic
tail were used: hSMOC (containing amino acid residues 32 to 555,
UniProt ID Q99835), hSMOC-CRD (containing amino acid
residues 190 to 555), and hSMOC-BRIL-V329F (which contains a BRIL domain inserted in place of intracellular loop 3 and
the V329F-inactivating point mutation). hSMOC constructs were
C-terminally tagged with 1D4 and N-terminally tagged with a
hemagglutinin (HA) tag.
Nb8 constructs
A synthetic gene for the active-conformation specific nanobody Nb8
(13) was obtained from GeneArt (Thermo Fisher Scientific) and
cloned into pHR-CMV-TetO2 to generate a fusion at its C terminus
to a HRV3C-mVenus-12His fragment.
PTCH1 constructs
Full-length PTCH1-WT and PTCH1-L2 were fused to a C-terminal
1D4 tag (amino acid sequence: TETSQVAPA) and cloned into the
pcDNA5-FRT-TO Flp-In vector (Thermo Fisher Scientific, catalog no.
V652020) to enable inducible expression in the 293Trex Flp-In cell system. PTCH1-L2, which carries a deletion of the second extracellular
loop (L2, amino acids 793 to 994), was a gift from J. Briscoe (32).
Cell lines
Human embryonic kidney (HEK) 293S GnTI cells [American Type
Culture Collection (ATCC), catalog no. CLR-3022], HEK293T cells
(ATCC, catalog no. CRL-3216), and Lenti-X cells (Takara Bio, catalog no. 632180) were purchased and used at low passages without
further authentication. Smo−/− mouse embryonic fibroblasts (MEFs)
used to stably express SMO variants have been described previously
(46) and were tested to ensure lack of endogenous SMO protein
using immunoblotting. All stable cell lines derived from Smo−/− cells
were generated as described previously (28) and authenticated by
immunoblotting to ensure stable expression of the transgene. Cell
lines were confirmed to be negative for mycoplasma infection. Stable
293Trex Flp-In cells (Thermo Fisher Scientific, catalog no. R780-07)
expressing PTCH1 were generated using PTCH1 constructs cloned into
the pcDNA5 FRT-TO Flp-In vector according to the manufacturer’s
instructions (4).
SMO expression and purification for crystallization
and binding studies
hSMOC-BRIL-V329F and its variants were expressed and purified
as reported previously (7). For other SMO proteins, constructs were
cloned into pHR-CMV-TetO2 (Addgene plasmid no. 113883) with
an added 3C-protease cleavable mVenus-1D4 tag for generation of
inducible stable HEK293S GnTI cell lines for expression (47).
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increase in SMO activity is unchanged by mutations in the TMD site
is more consistent with its role as an allosteric site regulating absolute
SMO signaling activity across the range of SHH concentrations. Our
data show that the fold change in SMO signaling activity in response
to SHH is mediated primarily by the orthosteric CRD site.
The most compelling evidence that the TMD site is the primary
focus of PTCH1 regulation is the observation that the signaling activity of SMO carrying mutations in the CRD is still partially sensitive
to PTCH1 (17, 27). For example, the basal signaling activity of
SMO-CRD (lacking the CRD) can be suppressed by overexpression
of PTCH1 (27). The common use of cholesterol as both an allosteric
and orthosteric agonist of SMO provides an explanation for these
previous results. Because PTCH1 reduces cholesterol accessibility
in the membrane, it can reduce cholesterol binding to both the CRD
and TMD sites, especially when PTCH1 is overexpressed at high,
nonphysiological levels used in these previous studies (Fig. 7B). The
ability of sterols to alter SMO activity by binding to the allosteric
TMD site is not unexpected—ligands that bind to allosteric sites
on GPCRs can function as agonists in their own right and change
receptor signaling activity (40). However, our results show that under
endogenous expression levels, PTCH1 primarily suppresses SMO
activity by preventing cholesterol occupancy of the CRD cholesterol–
binding site. Notably, PTCH1 is an immediate-early Hh target gene,
and its induction in response to SHH is a major negative-feedback
loop in the pathway. In tissues exposed to high SHH concentrations,
it remains possible that the high abundance of PTCH1 reduces
cholesterol binding to both the CRD and the TMD sites (Fig. 7B).
A recently proposed third model for SMO activation by sterols
suggests that there is continuous movement of sterols along a tunnel
that extends from the TMD to the CRD in SMO (15). SMO activation is triggered by sterol trapping in the TMD site, perhaps because
all the sterol-binding sites in this tunnel are occupied when membrane sterol levels rise. Our results contradict this model for two
reasons. First, SHH can increase the activity of mSMO carrying
a mutation in the TMD site (mSMO-Y398F) by the same extent
as mSMO-WT. Second, YFP-mSMO-CRD is poorly activated by
SHH although it remains normally responsive to both SAG and the
TMD-agonist KK174.
Most models for how PTCH1 inhibits SMO converge around
the concept that PTCH1, using its transporter function, reduces the
abundance of a sterol activator of SMO (1, 3, 41). Our observation
that the same sterol, 6-azi-20(S)-yne, interacts with both PTCH1
and SMO in an SHH-regulated manner supports a key tenet of this
model: The sterol activator of SMO should also be a substrate for
PTCH1. The photocrosslinking of 6-azi-20(S)-yne to PTCH1 can
be reduced by SHH, suggesting that it is a PTCH1 substrate, and
inactivation of PTCH1 by SHH increases the photocrosslinking of
6-azi-20(S)-yne to SMO. These results have interesting implications
for how PTCH1 inactivates SMO. Two distinct (but not mutually
exclusive) models for PTCH1-SMO regulation are as follows: (i)
PTCH1 reduces the cholesterol accessibility in the membrane compartment where SMO signals or (ii) PTCH1 directly inactivates SMO
using its extracellular domains to remove cholesterol from the SMO
CRD (Fig. 7C) (1, 2, 42, 43). Unlike cholesterol, oxysterols such as
6-azi-20(S)-yne do not accumulate in membranes because they carry
a second hydrophilic hydroxyl group on the iso-octyl chain (44).
The observation that PTCH1 reduces 6-azi-20(S)-yne cross-linking
to SMO suggests that it may also function by directly removing
sterols from the SMO CRD (Fig. 7C).
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Nb8-mVenus expression and purification
HEK293T Lenti-X cells were used to generate lentiviruses using the
pHR-CMV-TetO2 vector and subsequently used to infect HEK293T
cells for expression (47). Stable HEK293 T cells were expanded into
roller bottles in DMEM (Sigma-Aldrich, catalog no. D6546) supplemented with 1% l-glutamine, 1% NEAAs, and 10% FBS. To induce
expression, the medium was switched to 2% FBS and incubated at
37°C and 5% CO2 for 72 hours. Conditioned medium was harvested
and replaced with fresh complete DMEM supplemented with 2% FBS
and incubated for a further 72 hours before the final harvest. Cell
debris was removed from conditioned medium by centrifugation
(4000g for 10 min at room temperature) and filtration (0.2 M).
Clarified medium was concentrated and dialyzed into phosphate-
buffered saline (PBS; pH 8.0) using a QuixStand benchtop system
(Cytiva) connected to a 60-cm Xampler Cartridge (Cytiva) with a
10-kDa molecular weight cutoff. Concentrated medium was incubated
with TALON beads for 1 hour at room temperature. Protein-bound
beads were washed sequentially with PBS (pH 8.0) and PBS (pH
8.0) supplemented with 5 mM imidazole. Protein was eluted in 10
mM Hepes (pH 7.5), 150 mM NaCl, and 250 mM imidazole and
loaded onto a Superdex75 16/600, preequilibrated in 10 mM Hepes
(pH 7.5) and 150 mM NaCl. Peak fractions were pooled and concentrated, and aliquots were snap-frozen in liquid nitrogen for storage at −80°C.
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)
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Nb8 FSEC binding assay
Samples were prepared using purified hSMOC variants and
Nb8-mVenus in reaction volumes of 200 l and incubated for 1 or
24 hours. A total of 10 l was loaded onto a Superose 6 Increase
3.2/300 column (Cytiva) preequilibrated in 10 mM Hepes (pH 7.5),
150 mM NaCl, 0.02% GDN, and 0.002% CHS. Absorbance at 280 nm
was monitored, and mVenus fluorescence was measured using in-line
fluorescence detection (excitation, 515 nm; emission, 528 nm).
Nb8 bead binding assay
Purified hSMOC was incubated overnight at 4°C with an excess of
Nb8 and small molecule ligands (100 M each), where applicable.
Nb8 was immobilized onto TALON beads via its 12-His tag and
washed with 10× bead volumes of chilled 10 mM Hepes (pH 7.5),
150 mM NaCl, 0.02% GDN, and 0.002% CHS. Nb8 and any
bound SMO were eluted in 10 mM Hepes (pH 7.5), 150 mM NaCl,
0.02% GDN, 0.002% CHS, and 250 mM imidazole and analyzed by
Western blotting using the HA (monoclonal, clone 2-2.2.14, Thermo
Fisher Scientific, catalog no. 26183; Research Resource Identifier
(RRID): AB_2533056) tag appended to hSMO∆C.
Crystallization and data collection
SAG (EMD Millipore, SAG1.3) dissolved at high concentration in
dimethyl sulfoxide (DMSO) was added directly to the purified
hSMOC-BRIL-V329F protein after deglycosylation. The final concentration of SAG and its approximate molar excess with respect to
purified SMO at ~30 mg/ml (~465 M) was 8.35 mM SAG corresponding to an 18× molar excess. This resulted in a protein-SAG
solution with a final concentration of 2.5% DMSO. The hSMOCBRIL-V329F:SAG complex was reconstituted into lipidic cubic phase
by mixing with molten lipid in a mechanical syringe mixer (48).
Lipid, consisting of 10% cholesterol (Sigma-Aldrich) and 90% 9.9
monoacylglycerol (monoolein, Sigma-Aldrich), was heated to 42°C
before mixing with detergent-solubilized protein (with small molecule added) at ~30 mg/ml in a ratio of 3:2 (w/v). A Gryphon robot
(Art Robbins Instruments) was used to dispense 50 nl boluses of
protein-laden mesophase followed by 0.8 l of precipitant solution onto each of 96 positions on a siliconized glass plate and then
sealed with a glass coverslip in a “sandwich-plate” format. The
hSMOC-BRILV329F: SAG complex crystallized in 0.1 M MES
(pH 6.0), 0.09 to 0.12 M potassium formate, 24 to 27% (v/v) polyethylene glycol dimethyl ether 500, 0.5 mM zinc chloride, and 0.1 M
ammonium fluoride. Crystals were grown at 20°C and monitored
by eye, using a microscope fitted with cross-polarizers. Data collection details are provided in table S1.
Structure determination, refinement, and analysis
X-ray data were processed using the automated processing software
Xia2 (49). Typical individual hSMOC-BRIL-V329F crystals generated only 20° to 45° wedges of usable data due to radiation damage.
For the hSMOC-BRIL-V329F:SAG dataset, three such wedge datasets were merged. Data collection and processing statistics are shown
in table S1. The hSMOC-BRIL-V329F:SAG complex structure was
solved by molecular replacement in PHASER (50) using the structure
of hSMOC-BRIL-V329F [Protein Data Bank (PDB) 5L7D] (7) as
the search model. The asymmetric unit of each complex contained
two copies of SMO in the same antiparallel arrangement observed
previously (7). The structures were refined using BUSTER (51) and
PHENIX (52) using noncrystallographic and secondary structure
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Stable cell lines were expanded in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS; Gibco), 1% l-glutamine (Gibco), and 1% nonessential amino acids (NEAAs; Gibco). Cells were transferred to
Freestyle 293 expression medium (Gibco) (supplemented with
1% FBS, 1% l-glutamine, and 1% NEAAs) and grown in suspension
format at 37°C and 8% CO2 with 130 rpm shaking until a cellular
density of 3 × 106 to 4 × 106/ml was reached. Expression was induced
with doxycycline (0.1 g/ml; Sigma-Aldrich), and cells were harvested
after 72 hours by centrifugation (1500g for 10 min). Cell pellets
were resuspended in chilled 50 mM Hepes (pH 7.5), 300 mM NaCl,
and 1% protease inhibitor cocktail (Sigma-Aldrich, P8340). This was
supplemented with a final concentration of 1% 2,2-dioctylpropane-
1,3-bis--d-maltopyranoside (DMNG; Anatrace) and 0.1% cholesteryl
hemisuccinate (CHS; Anatrace) and incubated at 4°C for 90 min.
Cell lysate was clarified by centrifugation (50,000g for 30 min at
4°C), and the soluble fraction was retained. A total of 50 mM Hepes
(pH 7.5) and 300 mM NaCl were added to dilute the total detergent
concentration to 0.5% before adding Rho-1D4 antibody–coupled
(University of British Columbia) CNBr-activated sepharose beads
(Cytiva) and incubating for 2 hours. Protein-bound beads were
washed sequentially with 50 mM Hepes (pH 7.5), 300 mM NaCl,
10% glycerol, 0.007% DMNG, and 0.0007% CHS, followed by 50 mM
Hepes (pH 7.5), 300 mM NaCl, 10% glycerol, 0.06% glyco-diosgenin
(GDN; Anatrace), and 0.006% CHS, and last, with 50 mM Hepes
(pH 7.5), 300 mM NaCl, 10% glycerol, 0.02% GDN (Anatrace), and
0.002% CHS. Protein was eluted overnight with the addition of
3C protease (produced in-house) and concentrated to 250 l
using a Vivaspin 20 polyethersulfone 100,000-Da molecular weight
cutoff centrifugal concentrator (Sartorius). Protein was loaded
onto a Superose 6 Increase 10/300 column (Cytiva) preequilibrated
in 10 mM Hepes (pH 7.5), 150 mM NaCl, 10% glycerol, 0.02% GDN,
and 0.002% CHS. Peak fractions were pooled, concentrated,
and frozen.
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restraints. Extra electron density accounting for SAG, cholesterol, a
n-acetylglucosamine (NAG) moiety attached to N188 in the connector
region and one well-ordered monoolein molecule was apparent after
molecular replacement. Refinement statistics are provided in table S1.

Hh signaling assays
Quantitative PCR
A method to analyze Gli1 mRNA transcript levels was described
previously (2).
Immunoblotting
Whole-cell extracts were prepared in lysis buffer containing 150 mM
NaCl, 50 mM tris-HCl (pH 8), 10% NP-40, 1× protease inhibitor
(SigmaFast Protease inhibitor cocktail, EDTA-free; Sigma-Aldrich,
catalog no. S8830), 1 mM MgCl2, and 10% glycerol. After lysate
clarification by centrifugation at 20,000g, samples were resuspended
in 50 mM tris(2-carboxyethyl)phosphine and 1× Laemmli buffer for
30 min at 37°C. Samples were then subjected to SDS–polyacrylamide
gel electrophoresis, followed by immunoblotting with antibodies
against GLI1 [anti-GLI1 mouse monoclonal (clone L42B10); Cell
Signaling Technology, catalog no. 2643, RRID: AB_2294746], SMO
(rabbit polyclonal) (46), P38 (anti-P38 rabbit polyclonal; Abcam,
catalog no. ab7952; RRID: AB_306166), or a-tubulin [anti–a-TUBULIN
(clone DM1A), MilliporeSigma, catalog no. T6199, RR1D: AB_477583].
Detection of SMO at cilia using immunofluorescence
Smo−/− MEFs stably expressing SMO variants were seeded on acid-
washed coverslips and grown to confluency. The medium was then
Kinnebrew et al., Sci. Adv. 8, eabm5563 (2022)
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Ligand affinity assay to measure the interaction between
SMO and 20(S)-yne
Generation of 20(S)-yne–coupled beads and purification of SMO
lacking its C-terminal domain (hSMOC-BRIL-V329F) have both
been described in detail previously (7, 9). To test for bead binding,
purified hSMOC-BRIL-V329F diluted in binding buffer [50 mM
Hepes (pH 7.5), 300 mM NaCl, 10% glycerol, 0.03% n-Dodecylb-D-Maltoside (DDM), and 0.006% CHS] was incubated with oxysterol
beads (prewashed with binding buffer) overnight at 4°C in the presence or absence of 50 M MCD:20(S)-OHC or MCD:KK174.
Unbound material was removed by washing with binding buffer
three times, and the amount of SMO retained on the beads was
measured by elution from the beads using Laemmli buffer (30 min
at 37°C), followed by Western blotting using the HA (monoclonal,
clone 2-2.2.14, Thermo Fisher Scientific, catalog no. 26183; RRID:
AB_2533056) tag appended to hSMOC-BRIL-V329F.
Photoaffinity labeling of SMO, followed by click
chemistry–based detection
To measure the interaction between 6-azi-20(S)-yne and mSMO in
intact cells, 293 T cells (ATCC, catalog no. CRL-3216) were plated
in 10% FBS-supplemented DMEM and grown to 75% confluency.
The medium was exchanged to 5% LDS-supplemented DMEM (see
the “Cell culture and drug treatments for Hh signaling assays”
section), and N-terminally YFP-tagged mSMO (YFP-mSMO) was
transiently transfected using polyethylenimine. The following day,
medium was exchanged to 0.5% LDS-supplemented DMEM containing 1 M lovastatin, 10 M lithium mevalonate, and 1 M
U18666A. Twenty hours after YFP-mSMO transfection, 1 M 6-azi20(S)-yne was added in the presence or absence of SHH (1 M) for
1 hour. Cells were then moved to a metal rack on ice, medium
exchanged to ice-cold 1× PBS with 1× protease inhibitor cocktail
(SigmaFast Protease inhibitor cocktail, EDTA-free; Sigma-Aldrich,
catalog no. S8830), and irradiated with 365 nm light for 30 min to
trigger photocrosslinking to the diazirine.
After the photolabeling step, cells were immediately lysed for
1 hour at 4°C in lysis buffer [10% DDM, 0.1% SDS, 50 mM Hepes
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Cell culture and drug treatments for Hh signaling assays
All cells were grown in high-glucose DMEM (Thermo Fisher Scientific, catalog no. SH30081FS) containing 10% FBS (Sigma-Aldrich,
catalog no. S11150) and the following supplements (hereafter called
supplemented DMEM): 1 mM sodium pyruvate (Gibco, catalog
no. 11-360-070), 2 mM l-glutamine (GeminiBio, catalog no. 400106),
1× minimum essential medium NEAA solution (Gibco, catalog no.
11140076), penicillin (40 U/ml), and streptomycin (40 g/ml)
(GeminiBio, catalog no. 400109). Supplemented DMEM was sterilized through a 0.2-m filter and stored at 4°C.
To deplete cells of cholesterol in Fig. 3C, cells were seeded and
grown in supplemented DMEM containing 5% lipoprotein-depleted
serum (LDS) (Kalen Biomedical LLC) in place of 10% FBS. After
1 week of growth, cells were seeded for experiments in fresh 5%
LDS-supplemented DMEM and grown until confluent. Cells were
then serum-starved in 0.5% LDS-supplemented DMEM and simultaneously treated with 1 M U18666A (Sigma-Aldrich) for 20 hours
before the experiment. To rescue cholesterol depletion, 10 M cholesterol was delivered as methyl-b-cyclodextrin (MbCD):cholesterol complexes at time of serum starvation [generation of MCD:cholesterol
complexes is described in (5)].
To measure Hh responsiveness either by quantitative polymerase
chain reaction (PCR) or Western blot, cells were seeded in 10% FBS-
supplemented DMEM and grown to confluence. To induce ciliation,
cells were then serum-starved in 0.5% FBS-supplemented DMEM and
simultaneously treated. All treatment times and agonist/antagonist
concentrations are supplied in the figure legends. MCD:KK174
complexes were generated by the same method used to generate
MCD:cholesterol (5), where the MCD:cholesterol ratio is ~8.8:1,
and concentrations reported reflect the MCD concentration due
to their higher accuracy.

exchanged for 0.5% FBS-supplemented DMEM to induce ciliation,
and cells were treated with indicated treatments. Around 16 to
24 hours later, cells were fixed, blocked, and permeabilized in blocking buffer [0.1% Triton X-100, 1% donkey serum, bovine serum
albumin (10 mg/ml), and PBS]. Primary antibodies against SMO
(rabbit anti-SMO) (46) and ARL13B to detect primary cilia (guinea
pig anti-ARL13B) (53) were then added. After washing with
0.1% Triton X-100/PBS, secondary antibodies were added [donkey
anti-rabbit immunoglobulin G (IgG) (H + L) highly cross-adsorbed
secondary antibody, Alexa Fluor 488, Thermo Fisher Scientific
(Invitrogen, catalog no. A-21206, RRID: AB_2535792); and Alexa
Fluor 647 AffiniPure donkey anti-guinea pig IgG (H + L) (Jackson
ImmunoResearch Laboratories, catalog no. 706-605-148, RRID:
AB_2340476)]. Cells were then washed and mounted on glass slides.
Images were acquired on an inverted Leica SP8 laser scanning confocal microscope with a 63× oil immersion objective lens (numerical
aperture 1.4). Z stacks were acquired with identical acquisition
settings (gain, offset, laser power) within a given experiment. Analysis
was carried out as previously described (54) and analyzed using publically available scripts on GitHub (https://github.com/heybhaven/
Cilia_protein_quantification).
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6-azi-20(S)-yne synthesis
See Supplementary Methods.
Constructs used in atomistic molecular
dynamics simulations
The activated mSMO structure, bound to CRD and TMD cholesterols,
SAG, and Nb8, was obtained from the PDB (PDB 6O3C) (13).
Extracellular loop 3 (ECL3) was modeled using the mSMO sequence
based on an existing hSMOC-BRIL-V329F structure (PDB 5L7D)
(7) using MODELLER9.20 (55). PropKa (56) was used to identify three
residues with nonstandard pKa’s (E485, E522, and H73), which
were modeled accordingly. The following systems were constructed
for simulation: (i) mSMO bound to the nanobody, both cholesterols
and SAG, (ii) mSMO bound to CRD cholesterol and SAG, (iii)
mSMO with both CRD and TMD cholesterol bound, (iv) mSMO
bound to CRD cholesterol, (v) mSMO bound to TMD cholesterol,
and (vi) mSMO in its apo form. An additional system of mSMO
bound to three cholesterols (with the third cholesterol occupying a
“Mid” position in proximity to the linker region) was constructed on
the basis of the position of the upper 24(S),25-epoxycholesterol in
PDB 6XBM (fig. S3, C to H) (15). Systems of hSMO bound to CRD
cholesterol and SAG were constructed using the crystal structure in
this manuscript (Fig. 1B). The V329F mutant was reverted to WT,
the BRIL insert removed, and the intracellular loop 3 (ICL3) and
ECL3 were rebuilt on the basis of the position in an existing structure (PDB 4JKV, (18)) using MODELLER9.20 (55).
Each system was embedded in a 9 nm–by 9 nm 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine (POPC):cholesterol (3:1) bilayer
using CHARMM-GUI (57). Protein components were described
using the AMBER-ff14SB forcefield (58). Glycan GlcNAc attachments were modeled on N80 and N497 of mSMO and N188 and
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N493 of hSMO. Glycans were described using the GLYCAM-06j
forcefield with associated amino acid attachment parameters (59).
SAG parameters were derived using antechamber and the generalized
AMBER forcefield (GAFF2) with AM1-BCC used to optimize charge
interactions (60, 61). Lipids (including bound cholesterols) were
described using the AMBER-lipid17 forcefield (https://ambermd.org/
AmberModels_lipids.php). The system was solved using TIP4P-Ew
water and approximately 0.15 M NaCl (62, 63).
Atomistic molecular dynamics simulations
Simulations were performed using GROMACS 2019 (www.gromacs.
org). Each system was minimized using a steepest descent method
before Number of particles, Volume, Temperature (NVT) and
Number of particles, Pressure, Temperature (NPT) equilibration
steps of 5 ns each with restraints applied to protein, glycan, and
ligand coordinates when present. Atomistic simulations (5 × 300 ns)
were performed for each system. A 2-fs timestep was used and periodic boundary conditions applied. Temperature was maintained at
310 K using the Nosé-Hoover thermostat and a  T = 0.5-ps
coupling constant (64, 65). The Parrinello-Rahman barostat with a
P = 2.0-ps coupling constant and a compressibility of 4.5 × 10−5 bar−1
was used to maintain pressure at 1 bar (66). Electrostatics was
described using the particle-mesh Ewald method with a 1.2-nm
cutoff. Van der Waals interactions were modeled with a 1.2-nm
cutoff using the Verlet method. Long-range dispersion corrections
were applied for energy and pressure. All bonds were constrained
to the equilibrium lengths using the LINCS algorithm (67). Analysis
of hydrogen bonds between Y398 and the 3-hydroxyl group of the
TMD cholesterol was calculated using the HydrogenBondAnalysis
class of MDAnalysis and a 3-Å cutoff (68).
Allosteric pathways were calculated using allopath (github.com/
delemottelab/allosteric-pathways) (22). Each residue in mSMO was
assigned to a node. Source indices were defined as the C atoms of
residues lining the CRD (D99, L112, W113, Y134, I160, V161, and
I500). Sink indices were defined as the C atoms of the proposed
ionic-lock residues on 6/7 [R455 (R6.32), F459 (F6.36), and W539
(W7.55)], previously identified as playing a role in the activation of
SMO and class F GPCRs (14, 69). The heavy atoms of each cholesterol molecule were considered to comprise a lipid (“interactor”)
node. A cutoff value of c = 0.45 nm and an SD of  = 0.138 nm were
used to define heavy atom contacts during construction of the contact
map, as described previously (22). Information flow was calculated
in simulations of mSMO initiated from a ligand free apo state, with
cholesterol bound to the CRD alone, the TMD alone, or both sites.
Statistical analysis
Data analysis and visualization were performed in GraphPad Prism 8.
Model figures (Figs. 1A; 4, A and B; 5A; 6, A and C; and 7, A to C)
were made in Adobe Illustrator CS6. SMO structures (Figs. 1, B to
G, and I; and 2, A, F, and G; and figs. S1C, S2A, S3A, and S3, C to E)
were generated in PyMOL. Violin plots (figs. S1B and S2F) were
generated with default settings in GraphPad Prism 8; outliers were
excluded using the Identify Outlier function of GraphPad Prism 8
(ROUT method with a Q score = 10%). Mean and interquartile
ranges for each plot are denoted by solid and dotted lines, respectively. Curve fitting (Figs. 2, D and E; and 5, C, E, and F; and fig. S6A)
was carried out in GraphPad Prism 8 using a nonlinear regression
fit and the log(agonist) versus response, variable slope (four parameters) option.
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(pH 7.4), 150 mM NaCl, 1× protease inhibitor cocktail, and 10%
glycerol], and the resulting lysate was clarified by centrifugation
(20,000g for 30 min at 4°C). PTCH1 or SMO proteins were immunoprecipitated using antibody-coupled beads (1 hour at 4°C), and the
beads were washed five times with wash buffer [10% DDM, 0.1% SDS,
50 mM Hepes (pH 7.4), 150 mM NaCl, and 10% glycerol].
To detect mSMO or PTCH1 photolabeled with 6-azi-20(S)-yne,
an on-bead click reaction was performed to attach a biotin via the
alkyne handle on 6-azi-20(S)-yne. Beads were resuspended in 100 l
of wash buffer and supplemented with the following reagents in this
order: (i) 2.5 l of freshly prepared 200 mM sodium ascorbate, (ii) 1 l
of 10 mM tris-hydroxypropyltriazolylmethylamine, (iii) 2 l of 5 mM
PEG-biotin-azide, and (iv) 1 l of freshly prepared 100 mM copper
sulfate. After incubation at 37°C for 30 min, the reaction was
quenched, and the protein eluted using elution buffer [50 mM Hepes
(pH 7.4), 4% SDS, and 5 mM EDTA; 30 min with agitation at room
temperature]. The eluate was used for immunoblotting to detect total
PTCH1 and mSMO [PTCH1 was detected using an antibody recognizing its 1D4 tag: mouse monoclonal anti-1D4 (The University of
British Columbia; RRID: AB_325050); mSMO was detected using
the rabbit polyclonal antibody used previously (46)]; secondary
antibodies included IRDye 680LT donkey anti-mouse IgG (LI-COR
Biosciences; RRID: AB_2814906), IRDye 680LT donkey anti-rabbit
IgG (LI-COR Biosciences; RRID: AB_2814907), and photolabeled
PTCH1 and mSMO using streptavidin reagents (LI-COR IRDye
800CW Streptavidin, LI-COR Biosciences, catalog no. 926-32230).
Images were captured on the LI-COR Odyssey Imaging Platform.
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SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abm5563
View/request a protocol for this paper from Bio-protocol.
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All statistical analyses comparing two datasets used a Student’s
t test with Welch’s correction. When one dataset was compared to
more than one dataset, an unpaired ordinary analysis of variance
was used. All comparisons shown were prespecified. We note that a
small sample size (n = 3) makes it difficult to assess whether the
variance between different samples is comparable. Throughout the
paper, the P values for the comparisons from GraphPad Prism 8 are
denoted on the graphs according to the following key: not significant (ns) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤
0.0001. Unless indicated otherwise, all experiments were performed
three different times with similar results. Information about n values,
replicates, experimental trials, and exact P values for each figure is
provided below:
Replicates: In Figs. 2 (B and C), 3 (A to C and G), 4 (C, D, and F),
5 (B and D), and 6 (B, E, and F) and figs. S2 (G and H), S4 (A, C, and
D), S5 (B and C), and S6E, bars denote the mean value derived from
three independent measurements (biological replicates, n = 3). Each
independent measurement is an average of two technical replicates.
For all statistical tests, only the three biological replicates were considered (n = 3). In Figs. 2 (D and E) and 5 (C, E, and F) and fig. S6A,
error bars denote the SEM from three independent biological replicates. In Fig. 2H and fig. S3B, shaded bars correspond to the SEM.
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